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Background: Fatty acid-binding proteins (FABPs) play regulatory roles at the nexus of lipid metabolism and signaling.
Dyslipidemia in clinical manifestation frequently co-occurs with obesity, insulin resistance and hypertension in the
Metabolic Syndrome (MetS). Animal studies have suggested FABPs play regulatory roles in expressing MetS
phenotypes. In our family cohort of Northern European descent, transcript levels in peripheral white blood cells
(PWBCs) of a key FABPs, FABP3, is correlated with the MetS leading components. However, evidence supporting the
functions of FABPs in humans using genetic approaches has been scarce, suggesting FABPs may be under epigenetic
regulation. The objective of this study was to test the hypothesis that CpG methylation status of a key regulator of lipid
homeostasis, FABP3, is a quantitative trait associated with status of MetS phenotypes in humans.
Methods: We used a mass-spec based quantitative method, EpiTYPERW, to profile a CpG island that extends from the
promoter to the first exon of the FABP3 gene in our family-based cohort of Northern European descent (n=517). We
then conducted statistical analysis of the quantitative relationship of CpG methylation and MetS measures following
the variance-component association model. Heritability of each methylation and the effect of age and sex on CpG
methylation were also assessed in our families.
Results: We find that methylation levels of individual CpG units and the regional average are heritable and significantly
influenced by age and sex. Regional methylation was strongly associated with plasma total cholesterol (p=0.00028) and
suggestively associated with LDL-cholesterol (p=0.00495). Methylation at individual units was significantly associated
with insulin sensitivity, lipid particle sizing and diastolic blood pressure (p<0.0028, corrected for multiple testing for
each trait). Peripheral white blood cell (PWBC) expression of FABP3 in a separate group of subjects (n=128) negatively
correlated with adverse profiles of metabolism (βWHR = −0.72; βLDL-c = −0.53) while positively correlated with plasma
adiponectin (β=0.24). Further, we show that differential methylation of FABP3 affects binding activity with nuclear
proteins from heart tissue. This region that we found under methylation regulation overlaps with a region actively
modified by histone codes in the newly available ENCODE data.
Conclusions: Our findings suggest that DNA methylation of FABP3 strongly influences MetS, and this may have
important implications for cardiovascular disease.
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Lipids serve the body not only as major metabolic fuels
but also as membrane signaling transducers and modu-
lators of nuclear transcription factors [1]. Lipid homeo-
stasis is therefore under sophisticated regulation and is
well connected with other pathways of metabolism. An
unbalanced lipid state is often clustered with obesity, in-
sulin resistance and hypertension, which as a whole is a
common metabolic phenomenon called the Metabolic
Syndrome (MetS) [2]. Long-chain fatty acids (LCFAs)
are a major type of lipid but free LCFAs are insoluble in
the cytosol. Their movement within the cell requires fa-
cilitation of protein chaperones, the fatty acid binding
proteins (FABPs), a family of soluble cytosolic small
(14–15 kDa) polypeptides that bind with LCFAs [3].
There is increasing evidence that different types of
FABPs are important contributors to the development of
the MetS [4,5]. Furthermore, serum levels of the heart
type fatty acid binding protein (H-FABP), has been
shown to be associated with MetS in patients [6].
H-FABP, encoded by the FABP3 gene, is widely distrib-
uted with highest levels found in the heart and smaller
amounts present in slow skeletal muscle, testes, fast skel-
etal muscle, brain, kidney, lung, adrenal gland [7,8], and in
lymphocytes [9]. Studies in animal models have shown that
H-FABP helps maintain a balanced energy supply to heart
[10] and other body parts [11], regulates intramuscular fat
content and adipose tissue development [12], improves in-
sulin sensitivity [13], and regulates dopamine D2 receptor
function in the brain [14]. Such evidence would suggest a
potential role for H-FABP in MetS in humans. Indeed,
serum levels of H-FABP have been shown to be correlated
with body mass index (BMI), weakly correlated with hyper-
tension [15] and elevated in pre-diabetic patients [16], and
MetS patients [6]. Given that protein levels of H-FABP
fluctuate in parallel with mRNA levels, regulation is likely
to be at the transcriptional level [17]. In our cohort of ex-
tended Northern European families, the Metabolic Risk
Complications of Obesity Genes (MRC-OB) cohort, tran-
script levels of FABP3 from peripheral white blood cells
(PWBCs) has been found to be suggestively correlated
(p<0.1) with the MetS key axis phenotype defined by the
two leading components waist circumference (WC) and
homeostasis model assessment (HOMA) (unpublished
data) [2,18-20]. Given the fact that DNA sequence vari-
ation within FABP3 has rarely been found to be associated
with human disease states [21,22], it is possible that FABP3
transcription is regulated by epigenetic factors.
DNA CpG methylation is the most studied aspect of the
epigenetic code. It is fundamental to the biology of the cell
because newly added methyl groups can prevent the bind-
ing of transcription factors or attracts methyl-binding
domain (MBD)-containing proteins that can recruit tran-
scription suppressors such as histone deacetylases [23].There is increasing evidence that regulatory activity at the
level of DNA methylation plays an integral part in the
causation of complex human diseases, including cancer,
neuronal diseases, diabetes and obesity [24-28]. It is known
that cells of different tissue types display distinct patterns
in global CpG methylation [29]. In this study of roles of
epigenetic variation in disposing MetS traits, we assayed
DNA CpG methylation in white blood cells of peripheral
blood based on the following reasons. First, obesity is con-
sidered a low-grad inflammation state [30] and macro-
phage accumulation in adipose tissue is an early event in
this chronic inflammation [31,32]. Profiling CpG methyla-
tion in the tissue of peripheral blood thus could detect
MetS-specific epigenetic changes. Second, obtaining gen-
omic CpG methylation information using peripheral blood
is minimally invasive, making it possible to assay in large
number of our subjects. Third, there is evidence showing
concordance in CpG methylation profiles between periph-
eral blood and other tissue types [29] suggesting peripheral
blood can be a surrogate tissue source for epigenetic stud-
ies in humans. Recent efforts to identify epigenetic markers
associated with obesity and type 2 diabetes in humans, in-
cluding those done in peripheral blood, revealed a few can-
didate genes whose transcription is under epigenetic
regulation through modifications of the methylation of
CpG sites within or near promoter regions [33-36]. Studies
that carefully examine the characteristics of CpG methyla-
tion in family settings in relation to complex diseases like
obesity and metabolic syndrome are, however, very scarce.
We report here our findings on the methylation profiles of
a CpG island near FABP3, a gene whose product H-FABP
is of high biological importance in energy and metabolic
homeostasis.
A recent pilot study examining the effects of DNA
methylation on cardiovascular-related phenotypes within
the San Antonio Family Heart Study (SAFHS) [37] showed
suggestive correlation between methylation levels at a
CpG site within exon 1 of FABP3 and several metabolic
syndrome (MetS)-related phenotypes, including HDL-
cholesterol (p=0.0017) and fasting insulin (p=0.0048) (un-
published data; p-values not corrected for multiple testing).
We therefore conducted a study to test whether the pro-
posed function of FABP3 in MetS is under epigenetic regu-
lation using families of our MRC-OB cohort shown to be
highly informative for finding genetic elements important
for MetS-associated lipid pathways [38,39]. To finely dissect
the relationship between quantitative methylation and the
clinical outcomes as well as the biological precursor pheno-
types expressed in MetS, we examined our extensively
phenotyped cohort and identified several CpG sites that
were associated with lipids, insulin and blood pressure mea-
sures. To our knowledge, this is the first study describing a
role for epigenetic regulation of FABP3 in metabolic
syndrome traits.
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Subjects and phenotypes
The study cohort consists of 517 individuals repre-
senting 40 extended nuclear families. Details of recruit-
ment and phenotyping procedures have been described
previously [40]. Briefly, each family was recruited
through an obese proband (BMI ≥ 30) with the minimal
requirement of the availability of one obese sibling and
one never-obese (BMI ≤ 27) sibling and availability of at
least one, preferably both, of the parents. Clinical pheno-
types included weight, height, BMI, waist circumference
(WC), hip circumference (HC), waist to hip ratio
(WHR), fasting glucose (FG), fasting insulin (FI), insulin
to glucose ratio (IGR), homeostasis model assessment
(HOMA), plasma triglycerides (TG), total cholesterol
(TC), low density lipoprotein- cholesterol (LDL-c) and
calculated LDL-c levels (cal. LDL-c), high density
lipoprotein-cholesterol (HDL-c), systolic and diastolic
blood pressure (sBP and dBP) and pulse. Biological phe-
notypes were determined according to standard pub-
lished procedures, and included: measurement of total
fat mass in kilograms and percentage (Fatkg and Fatpct),
and lean mass in kilograms and percentage (Leankg and
Leanpct) by Dual-emission X-ray absorptiometry
(DEXA) [41]; total abdominal, visceral and subcutaneous
fat sizes (TAF, VF and SubQF) as measured by computed
tomography (CT/MRI) scans of an average of three sec-
tions at the fourth lumbar spine [42]; resting energy ex-
penditure (REE) and respiratory quotient (RQ) as
measured in resting subjects using a Deltatrac Indirect
Calorimeter (Sensor Medics, VIASYS Healthcare,
Conshohocken,PA) after a 10 hr fast; insulin/glucose re-
sponsiveness indices of insulin sensitivity (SI), glucose
effectiveness (SG), acute insulin response to glucose
(AIRG) and disposition index (DI) by Minimal Model
[43]; lipids/lipoprotein sizing [HDL median diameter
(HMED), LDL-cholesterol median diameter (LMEDn),
LDL-cholesterol dominant peak diameter (LDLppd) and
apoB-containing non-HDL median diameter (BMED)
which includes VLDL, ILDL, LPα and LDL] as measured
by polyacrylamide gradient gel electrophoresis [44]; cir-
culating levels of adiponectin and leptin measured by a
double antibody equilibrium radioimmunoassay (RIA)
(Millipore Corporation, Billerica, MA); and TNF-alpha,
interleukin-1beta (IL-1β) and interleukin-6 (IL-6)] levels
that were measured as previously described [45]. In-
formed consent was obtained from the participating sub-
jects. All study procedures for all participants were
approved by the Institutional Review Boards of the Med-
ical College of Wisconsin (HRRC#013-00).
Quantitative methylation analysis using EpiTYPERW
Methylation analysis was performed as described previ-
ously by Lee et al. [46]. Approximately 500 ng ofgenomic DNA isolated from PWBCs was bisulfite modi-
fied (BSM) using the EZ-96 DNA Methylation Kit fol-
lowing the manufacturer’s protocol (Zymo Research;
Irvine, CA). Methylated and unmethylated control DNA
(Zymo) were also bisulfite modified to confirm complete
bisulfite modification and for quality control.
Three PCR primer regions were designed to cover the
entire region of interest within the promoter and first
exon region of FABP3 (for details of their sequences and
chromosomal positions, see Additional file 1: Table S1).
EpiTYPERW CpG methylation profiling was done per
manufacturer instruction, with modifications as de-
scribed here. BSM DNA was PCR amplified using T7-
promoter tagged primers specific for single-stranded,
bisulfite-modified DNA. PCR amplification of each
amplicon was performed in a 6 μl reaction volume (1x
PCR Buffer, 0.75 mM MgCl2, dNTPs (2.5 mM each),
0.20 mM each primer, 0.05 μl HotStar Taq DNA poly-
merase (Qiagen; Valencia, CA) & 2 μl bisulfite-modified
DNA). To ensure accurate DNA methylation detection,
all bisulfite-modified samples were PCR amplified in
triplet along with five methylation controls (obtained
from the Zymo Control Set). These included 100%, 75%,
50%, 25% and 0% methylated bisulfite-converted DNA,
obtained from appropriate combination of the methyl-
ated and unmethylated control DNA samples. Unincor-
porated dNTPs from the PCR reaction were neutralized
using shrimp alkaline phosphatase (SAP), and double-
stranded cRNA was created from the template by
in vitro transcription. The cRNA was base-specifically
cleaved with RNase A, generating fragments (CpG units)
containing any number of CpG sites. The cleavage prod-
ucts were then spotted onto silicon chips (SpectroCHIP
II, Sequenom) using a nanodispenser. Adenine and
guanine differ in mass by ~16 daltons; therefore, each
CpG site that is methylated creates a 16 dalton change
that is detectable by matrix assisted laser desorption
ionization-time of flight mass spectrometry (MALDI-
TOF MS) (MassARRAYW system, Sequenom).
Methylation percentage for CpG sites within a sample
of genomic DNA was calculated with the EpiTYPER
software which generates predicted “CpG units”, which
may contain one or more CpG sites, and pre-calculates
their mass. The abundance of each fragment (signal/
noise level in the spectrum) detected by the
MassARRAYW system is indicative of the amount of
DNA methylation in the interrogated sequence. The
CpG sites whose methylation intensity cannot be unam-
biguously determined by the MassARRAYW technology
were excluded from further analyses (see legend of
Figure 1 for their locations). In some cases, CpG sites
were within the same CpG unit and were unable to be
differentiated; CpG sites 6/7, 10/11/12, 17/18 and 21/22
were therefore assessed as a single site. CpG sites 3a and
Figure 1 CpG methylation profile of FABP3 promoter/1stexon region. A total of 28 CpG sites were identified within or immediately upstream
to the CpG island spanning the boundary between the promoter and the first exon of FABP3 gene. Methylation values at each CpG loci
measured in our MetS cohort (y-axis) were averaged and plotted against their chromosomal positions (x-axis). CpG methylation levels are
depicted by bars with standard deviations shown in error bars. A graphical representation of the FABP3 region under investigation is shown
below the bar graph. Squares represent the CpG units that passed the quality control standard (see Materials and Methods). Triangles represent
the CpG units that did not pass the quality control criteria and were therefore not analyzed further. The location of the identified CpG island is
highlighted in blue. Transcription start site, position of the start codon and transcription elements that were previously identified in the promoter
region (53) are also shown.
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the same mass, and therefore could not be distinguished
from each other. In this case, the methylation level is
recorded as an average of the two fragments. We have
rejected the entire methylation datasets of 13 subjects
(2.5%) with calling rate lower than 95%. Of the remaining
subjects, we excluded data points (4.8% of all measure-
ments) that have standard deviation higher than 0.1.
Transcriptional profiling
Genome-wide transcriptional profiles of a subset of the
cohort (128 individuals from 55 families) were obtained
as previously described [47] with modifications. Briefly,
for each individual 2.5 ml blood was collected into a
PAXgeneW Blood RNA Tube (BD, Franklin Lakes, NJ)
following an overnight fast. Total RNA was isolatedfrom each tube using the PAXgene Blood RNA Kit
(Qiagen, Valencia, CA) and anti-sense RNA (aRNA) was
synthesized using the MessageAmp II-Biotin aRNA kit
(Ambion, Austin, TX). A total of 1.5 μg aRNA was hy-
bridized to Illumina HumanWG-6 version 2 or version 3
chips (Illumina, San Diego, CA) and expression detected
on the IlluminaW BeadArray™ 500GX Reader. Illumina
GenomeStudio software (version 2010.3) was used for
preliminary data analysis with standard background
normalization.
Electrophoretic mobility shift assay
Electrophoretic Mobility Shift Assay (EMSA) was
performed on completely methylated and completely
unmethylated DNA from the promoter region. First,
PCR amplification of the target area was performed in a
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MgCl2, 2 mM each primer, 0.04 μl HotStar Taq DNA
polymerase (Qiagen; Valencia, CA), and 4 μl CEPH
(Centre d’Etude du Polymorphisme Humain) DNA] with
an annealing temperature of 58°C for 40 cycles. Oligo-
nucleotide primers were synthesized from IDT technolo-
gies (Coralville, IA) as follows; forward primer: 50
TTGCTGTCCACTAGCTTCCA 30 and reverse primer:
50/biotin/ CCTCCTGGGTGAGCCCTA 30. PCR prod-
ucts were size-selected using Invitrogen 2% Size
Select™ E-GelW and then purified with the PCR Purifica-
tion Kit (Qiagen; Valencia, CA) per the manufacturers’
instructions.150 ng of the biotin-labeled DNA was
treated with CpG Methylase (Zymo; Irvine, CA), by incu-
bating at 30°C overnight, per manufacturer instruction.
After an initial 2 hour incubation period, additional CpG
Methylase (1 uL) was added, to drive the methylation to
completion. The enzyme was inactivated at 65°C for
20min and the reaction was cleaned with the MinElute
Reaction Cleanup Kit (Qiagen; Valencia, CA). To verify
methylation, 50 ng each of methylated and unmethylated
DNA was digested with HpaII (New England BioLabs; Ips-
wich, MA) at 37°C for 1 h. The enzyme was inactivated at
65°C for 20min. The reaction was cleaned with the
MinElute Reaction Cleanup Kit (Qiagen; Valencia, CA)
and checked by gel electrophoresis. Quantification of
DNA was performed using Promega QuantiFluor dsDNA
System (Madison, WI), as per the manufacturer’s
multiwell plate instruction and plates read on a Thermo
Scientific Varioskan Flash (Rockford, IL).
Electrophoresis mobility shift assays (EMSA) were
performed using the LightShift EMSA kit (Thermo Scien-
tific; Rockford, IL) with adaptations from previous studies
[39,48]. For EMSA, methylated-biotin labeled DNA and
unmethylated biotin-labeled DNA were used in separate
reactions. Human heart nuclear lysate (left ventricle) was
purchased from ProSci Incorporated (Poway, CA) and
3 μg was pre-incubated for 10 min on ice with 1 μg of poly
(dI-dC), 10X Binding Buffer, 1% NP-40, MgCl2 and gly-
cerol. Nuclear proteins were then incubated with 0.1 ng of
methylated (or unmethylated for control) biotin-labeled
DNA for 30 min on ice, analyzed on 6% Novex DNA re-
tardation gels (Invitrogen; Carlsbad, CA) and electroblotted
onto a positively charged nylon membrane (Invitrogen;
Carlsbad, CA). Detection of protein/DNA complexes was
achieved following incubation of the membrane with
streptavidin-horseradish peroxidase and development with
luminal substrate (Thermo Scientific; Rockford, IL). Light
emission was captured on X-ray film.
Statistical analysis
Descriptive statistics were computed using the R pro-
gramming language [49]. Quantitative genetic analyses
were performed using SOLAR [50]. Briefly: based onpedigree data, a kinship coefficient was computed for
each pair of study subjects equal to the expected propor-
tion of alleles shared identical by descent (= 0 for indi-
viduals without common ancestors in the pedigrees).
Using this information, the phenotypic covariance be-
tween pairs of individuals was decomposed into
expected variances due to additive genetics effects and
residual random effects, respectively. The standardized
additive genetic variance of a phenotype is its heritability
(h2). All subsequent tests of the fixed effects of methyla-
tion status also included these random effects, so the
non-independence of related subjects was properly
accounted for. We also included in all models the fixed
effects of sex, age, age2, sex by age interaction, and sex
by age2 interaction.
To meet the distributional assumptions of the
variance-decomposition tests, all phenotypes – the MetS
traits as well as the percent-methylation measures –
were normalized by inverse-Gaussian (rank-normal)
transformation. All genetic models were tested by likeli-
hood maximization in SOLAR. The test statistic for each
hypothesis was equal to twice the difference in loge(like-
lihood) of the test model and its respective null. For
fixed effects, this test statistic is distributed as chi-
squared with degrees of freedom equal to the number of
parameters under test; for h2 (which is tested on its
lower boundary, h2= 0) the distribution is a 0.5:0.5 mix-
ture of χ21 and a point mass at zero [51].
Gene expression microarray data were available for a
total of 128 samples (48,803 probes, Illumina Beadchips
v3 arrays). The number of probe transcripts detectable
at p≤0.05 by BeadStudio software was counted, a false
discovery rate (FDR) was computed across all probes,
and transcripts detectable at 5% FDR were retained. Ex-
pression levels were log2 transformed and inverse-
quartile normalized. Transformed and normalized ex-
pression levels for probes that mapped to FABP3 were
tested for correlation with phenotypes of interest in
models that included the random effect of kinship.
Correction for multiple testing of the effects of the CpG
units was based on the effective number of independent
units given the potential correlation among units in the
same genomic region. We used a method originally de-
vised for association tests of SNP variants [52] as
implemented in SOLAR [50]. The Bonferroni-Šidák sig-
nificance threshold for multiple tests in the FABP3 region
was calculated using alpha = 0.05 (significant) and alpha =
0.1 (suggestive), and the effective number of tests.
Results
Clinical outcome and biological precursor phenotypes of
the MetS study cohort
Table 1 shows the sex-specific means (±standard devi-
ation, STD) of the 42 MetS phenotypes measured in 517
Table 1 Phenotypic characteristics and heritability estimates of the MetS cohort
Trait Mean ± STD (Male) Mean ± STD (Female) Heritability ± SE
Body Composition Weight, kg 97.73 ± 26.30 90.28 ± 25.92 0.40±0.10
Height, cm 176.34 ± 6.97 163.46 ± 6.95 0.69±0.07
BMI, kg/m2 31.45 ± 8.40 33.95 ± 10.19 0.43±0.09
Waist circumference (WC), cm 102.12 ± 18.34 97.77 ± 20.16 0.33±0.09
Hip circumference (HC), cm 109.44 ± 16.52 117.95 ± 20.40 0.43±0.10
Waist to Hip ratio (WHR) 0.93 ± 0.08 0.83 ± 0.09 0.23±0.09
Total Fat Mass (Fatkg), kg 28.49 ± 13.81 38.01 ± 14.68 0.41±0.11
Total Fat Mass (Fatpct),% 29.78 ± 9.02 43.94 ± 7.79 0.39±0.10
Total Lean Mass (Leankg), kg 62.53 ± 8.23 45.81 ± 8.44 0.55±0.09
Total Lean Mass (Leanpct), % 74.29 ± 39.60 57.74 ± 28.07 0.38±0.10
Subcutaneous Fat (SubQF), g 72.61 ± 44.52 93.54 ± 48.94 0.57±0.10
Visceral Fat (VF), g 57.32 ± 30.54 42.86 ± 29.17 0.34±0.10
Total Abdominal Fat (TAF), g 128.96 ± 66.28 136.82 ± 69.39 0.54±0.10
Respiratory Quotient (RQ) 0.83 ± 0.09 0.83 ± 0.08 0.30±0.09
Resting Energy Expenditure (REE), kcal/24 hrs 1931.18 ± 327.99 1620.70 ± 292.96 0.34±0.10
REE/weight, kcal/24hrs/kg 20.17 ± 3.64 18.62 ± 3.21 0.37±0.11
REE/Lean mass (REE/lean), kcal/24hrs/kg 30.37 ± 3.83 35.18 ± 4.28 0.36±0.11
Glucose and Insulin Responsiveness Fasting Glucose (FG), mg/dl 88.53 ± 30.35 87.14 ± 30.83 0.51±0.09
Fasting Insulin (FI),μU/ml 15.96 ± 12.90 19.24 ± 24.53 0.38±0.08
Insulin/glucose (IGR) 0.27 ± 0.76 0.29 ± 0.93 0.35±0.08
Homeostasis model assessment (HOMA) 3.52 ± 3.04 4.63 ± 9.92 0.38±0.08
Insulin Sensitivity (SI), (× 10-4/min/μU/ml) 3.32 ± 2.94 2.86 ± 2.79 0.20±0.10
Glucose Effectiveness (SG), min-1 0.02 ± 0.01 0.02 ± 0.02 0.12±0.10
Acute Insulin Response to glucose (AIRG), μU/ml × 10min 537.09 ± 477.19 416.81 ± 338.89 0.12±0.08
Disposition Index (DI), AUC (Insulin0-10 min) × SI 1367.12 ± 1188.95 1054.62 ± 996.43 0.25±0.09
Lipid Homeostasis Triglycerides (TG), mg/dl 135.40 ± 208.06 106.45 ± 64.89 0.52±0.11
Total cholesterol (TC), mg/dl 193.08 ± 45.75 189.06 ± 40.03 0.29±0.08
LDL-cholesterol (LDL-c), mg/dl 131.44 ± 40.55 126.95 ± 36.61 0.33±0.09
Calculated LDL-C (cal. LDL-c), mg/dl 134.83 ± 55.40 126.53 ± 38.97 0.45±0.10
HDL-cholesterol (HDL-c), mg/dl 38.24 ± 12.05 43.65 ± 18.63 0.69±0.08
HMED, nm 8.83 ± 0.31 9.19 ± 0.50 0.40±0.10
LMEDn, nm 27.03 ± 0.70 27.26 ± 0.97 0.46±0.11
LDL_PPD, nm 27.17 ± 0.95 27.99 ± 1.30 0.61±0.10
BMED, nm 27.67 ± 1.09 28.07 ± 1.28 0.42±0.10
Cardiovascular Performance Systolic Blood Pressure (sBP), mmHg 128.69 ± 15.34 124.90 ± 19.07 0.22±0.09
Diastolic Blood Pressure (dBP), mmHg 78.97 ± 12.18 75.68 ± 10.74 0.22±0.10
Pulse, beats/min 68.59 ± 9.85 72.93 ± 21.31 0.15±0.08
Adipokines and Cytokines Adiponectin, ng/ml 6.66 ± 3.06 9.47 ± 4.77 0.60±0.09
Leptin, ng/ml 11.07 ± 10.90 25.34 ± 15.19 0.41±0.09
TNF-alpha, pg/ml 4.26 ± 2.67 3.74 ± 2.53 0.38±0.09
Interleukin-1 beta (IL-1β) 0.40 ± 0.95 0.46 ± 0.96 0.23±0.10
Interleukin-6 (IL-6) 3.75 ± 8.53 5.42 ± 9.44 0.20±0.09
The mean +/− standard deviation is shown for each of the 42 MetS phenotypes. Heritability of MetS phenotypes estimated in these 40 extended families (n=517)
is shown with standard errors (SE). For nomenclature of the 42 phenotypes, refer to Materials and Methods.
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pean descent. 58.9% of the cohort is female, the average
age of the cohort is 43.6y and the average BMI is
32.937 kg/m2. Phenotypes have been grouped into 5 cat-
egories (body composition phenotypes, glucose and in-
sulin responsiveness, lipid homeostasis, cardiovascular
performance and adipokines/cytokines) that reflect
major components of MetS. Table 1 also shows the esti-
mated heritability of each MetS phenotype in our fam-
ilies. Heritability of these phenotypes varies from 0.12
for glucose effectiveness (SG) to 0.69 for height and
HDL cholesterol.
CpG methylation profile of the promoter region of FABP3
The 50 region immediately upstream of the transcription
start site of FABP3 has been shown to be sufficient to
drive the expression of this gene in a mouse model [53].
We examined the genomic sequence adjacent to the
transcriptional start site (TSS) and identified a CpG is-
land that spans the region upstream of the TSS (−132 bp)
to the first exon (+185 bp). We included in our analysis
of CpG sites that were located immediately upstream to
the beginning of the island. This 533 bp region contained
28 CpG sites (Figure 1), of which the methylation status
of 24 sites could be measured by EpiTYPERW technol-
ogy. For certain adjacent CpG sites, EpiTYPERW could
only report their methylation status as one unit. We
therefore arbitrarily refer to all successfully measured
CpG loci as units. A total of 17 CpG units passed our
stringent quality control criteria (see Materials and
Methods for details). CpG units within the first exon
exhibited generally higher methylation levels than those
upstream of the TSS.
Genetic analysis of CpG methylation with MetS traits in our
family cohort
Table 2 shows the heritability of the methylation status
at each of the 17 CpG units that we successfully profiled.
We found that except for three CpG units (2, 3 and 17/
18), the methylation patterns of these units are genetic-
ally shared by family members, although their heritabil-
ity levels varied greatly from 0.15 to 0.48. We tested for
the effect of age and sex on methylation status of these
units and found that the methylation level at several
units is affected by age and sex. For example, the methy-
lation status of site 9 is positively correlated with age
(βage = 2.90E-04, p = 3.95E-05) whereas CpG site 19
was influenced by sex (βsex = 1.30E-02, p = 3.88E-04).
For these CpG loci, the influence of age on their methy-
lation levels is different from that of sex, with some units
showing a greater influence of age and others being af-
fected more by sex.
We then tested for association of quantitative methyla-
tion levels of these 17 CpG units, as well as averagemethylation across the entire region assessed, with 42
MetS phenotypes. Phenotypes that were significantly as-
sociated (p<0.0028, alpha = 0.05 corrected for 18 CpG
loci; pα=0.05=6.7×10
-5, if all 42 MetS phenotypes are
treated as non-independent traits in one hypothesis)
with the methylation status of at least one site or the re-
gional average are shown in Table 3 and Figure 2. The
strongest association was that between overall average
methylation and total cholesterol level (p=0.00028).
Methylation at units 13 and 21/22 was associated with
diastolic blood pressure (p=0.00129) and insulin sensitiv-
ity (p=0.0014), respectively. Methylation of site 17/18
within the first exon was associated with apoB-
containing non-HDL particle size (BMED), which in-
cludes VLDL, ILDL, LPα and LDL (p = 0.0025). Regional
average methylation was also suggestively associated
(p<0.0056, alpha = 0.10 corrected for 18 tests) with LDL
cholesterol (p = 0.0050). We observed that the propor-
tion of trait variance that can be explained by associated
CpG methylation status is comparable to previously
reported contributions of individual SNPs to the disease
trait (1-3%) (Table 3). We also estimated the back
transformed absolute value in each associated MetS
phenotype per percentile change in methylation of par-
ticular CpG loci. For instance, we found for every 1% in-
crease in regional average methylation of FABP3, the
plasma level of total cholesterol was estimated to in-
crease by 6.60 mg/dl.
Genetic analysis of the relationship between PWBC
expression of FABP3 and MetS traits related to lipids and
adipokines in the expression study cohort
In parallel to the methylation analysis of FABP3 in relation
to the MetS traits in our family cohort, we analyzed the
expression levels of this gene in PWBCs in a separate
group of subjects from our MRC-OB collections. Table 4
shows the sex-specific means (±standard deviation, STD)
of the 15 MetS phenotypes measured in 128 individuals of
55 extended families of Northern European descent. 52.3%
of the cohort is female, the average age of the cohort is
41.1y and the average BMI is 31.95 kg/m2.
Specifically, we analyzed in our family cohort the rela-
tionship of levels of FABP3 transcripts in PWBCs with
quantitative measures of MetS phenotypes focusing on the
lipids, fat distribution (WHR) and plasma levels of two
key protein hormone exclusively produced by adipose tis-
sue (adiponectin and leptin). Table 5 shows the
phenotype-specific correlation beta values (±standard
error) of FABP3 expression in PWBCs. In general, the
gene expression of FABP3 correlated positively with MetS
phenotypes that are known to have beneficial effects in
metabolic profiles including HDL-cholesterol (βHDL-c =
0.42) and adiponectin (βadiponectin = 0.24). In contrast,
FABP3 expression in the PWBCs correlated negatively
Table 2 Heritability and correlations with age and sex of methylation status near FABP3 start codon
CpG site Heritability ±SE Pheritability β±SEage Page Variance explained age β±SEsex Psex Variance explained sex
FABP3_1 0.21 ± 0.07 2.85E-05 1.70E-04 ± 1.00E-04 1.03E-01 2.99E-03 1.90E-03 ± 3.50E-03 5.87E-01 2.19E-04
FABP3_2 0.05 ± 0.07 1.89E-01 1.60E-04 ± 4.90E-05 1.64E-03 1.03E-02 −7.30E-04 ± 1.60E-03 6.59E-01 1.98E-04
FABP3_3 0.09 ± 0.08 1.11E-01 1.50E-04 ± 6.20E-05 1.32E-02 1.41E-02 4.60E-03 ± 2.00E-03 2.34E-02 5.55E-03
FABP3_4 0.18 ± 0.08 4.39E-03 4.00E-05 ± 5.00E-05 4.11E-01 1.27E-03 2.70E-03 ± 1.60E-03 8.93E-02 3.10E-03
FABP3_5 0.15 ± 0.07 7.38E-03 1.10E-04 ± 3.20E-05 7.44E-04 1.41E-02 5.40E-04 ± 1.00E-03 6.06E-01 7.51E-05
FABP3_6/7 0.17 ± 0.08 5.15E-03 1.20E-04 ± 3.20E-05 1.09E-04 1.52E-02 2.50E-04 ± 1.10E-03 8.11E-01 2.61E-05
FABP3_8 0.17 ± 0.08 3.23E-03 −2.00E-05 ± 9.80E-05 8.35E-01 3.09E-04 6.20E-03 ± 3.20E-03 5.23E-02 3.44E-03
FABP3_9 0.48± 0.08 4.53E-17 2.90E-04 ± 7.10E-05 3.95E-05 2.09E-02 −7.60E-04 ± 2.40E-03 7.48E-01 1.31E-04
FABP3_10/11/12 0.19 ± 0.09 4.40E-03 2.80E-04 ± 6.80E-05 5.77E-05 2.05E-02 6.00E-03 ± 2.20E-03 6.55E-03 7.31E-03
FABP3_13 0.46 ± 0.10 1.06E-09 2.20E-04 ± 1.10E-04 3.75E-02 8.40E-03 3.90E-03 ± 3.50E-03 2.66E-01 1.58E-03
FABP3_14 0.48 ± 0.10 2.41E-09 2.80E-04 ± 1.30E-04 3.51E-02 7.52E-03 1.30E-02 ± 4.40E-03 2.50E-03 1.11E-02
FABP3_15 0.15 ± 0.07 3.92E-03 −2.80E-04 ± 1.40E-04 4.77E-02 4.15E-03 4.50E-03 ± 4.60E-03 3.34E-01 9.95E-04
FABP3_16 0.32 ± 0.10 1.90E-05 2.30E-04 ± 8.70E-05 8.20E-03 1.04E-02 6.30E-03 ± 2.80E-03 2.72E-02 5.63E-03
FABP3_17/18 0.03 ± 0.06 2.80E-01 1.30E-04 ± 1.40E-04 3.49E-01 9.21E-04 7.60E-03 ± 4.70E-03 1.03E-01 2.78E-03
FABP3_19 0.26 ± 0.09 5.76E-05 −3.30E-04 ± 1.10E-04 2.97E-03 5.46E-03 1.30E-02 ± 3.60E-03 3.88E-04 1.16E-02
FABP3_20 0.41 ± 0.09 4.52E-09 1.00E-05 ± 9.30E-05 8.79E-01 2.61E-05 8.10E-03 ± 3.10E-03 8.91E-03 3.88E-03
FABP3_21/22 0.14± 0.08 2.15E-02 −7.00E-05 ± 1.60E-04 6.34E-01 5.56E-04 −5.50E-03 ± 5.40E-03 3.06E-01 2.50E-03
FABP3_AVG 0.22 ± 0.07 9.35E-06 9.30E-04 ± 6.10E-04 1.24E-01 5.00E-03 6.00E-02 ± 2.00E-02 2.23E-03 5.99E-03
Heritability (±SE) estimates are shown for the 17 individual CpG units and their average. Significance p-values for heritability estimates are shown. Association β
(±SE) values, their associated significance p-values, and the portion of total variance in methylation explained by age and sex are also shown.
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http://www.biomedcentral.com/1755-8794/6/9with TC (βTC = −0.25), LDL-c (βLDL-c = −0.53), TG
(βTG = −0.20), and WHR (βWHR = −0.72), whose elevation
is usually linked with an unhealthy profile of metabolism.
The methylation status of the concise promoter affects
FABP3 binding of heart nuclear proteins
We hypothesized that CpG methylation status is able to
influence the expression of FABP3 by modifying the
binding affinity of the region for specific transcription
factors. We tested this hypothesis by performing a
methylation-specific EMSA using nuclear extract from
human left ventricle tissue. In this EMSA, instead of in-
terrogating the binding capacity of the two alternative
nucleotides of a SNP as is routinely done in an EMSA
experiment, we applied it to completely methylated and
completely unmethylated promoter regions, that were
chosen based upon the location of previously deter-
mined transcription elements (53). As shown in Figure 3,
in the presence of heart nuclear proteins, two bands
shifted from the pool of unbound biotin-labeled DNATable 3 Associations between MetS traits and methylation st
MetS trait CpG Site β±SE Var
TC (mg/dl) FABP3_AVG 0.17* ± 0.045 0.02
BMED (nm) FABP3_17/18 −0.15* ± 0.05 0.02
DBP (mmHg) FABP3_13 −0.16* ± 0.049 0.01
SI (× 10-4/min/μU/ml) FABP3_21/22 −0.16* ± 0.051 0.01
The traits or CpG units that showed any significant associations are presented. For
(varexp), and the absolute change in that trait attributable to methylation of the spprobes to higher molecular weight, suggesting nuclear
protein(s) from this tissue can bind with the FABP3 pro-
moter sequence. Further, completely methylated DNA
sequences bound with higher affinity to these unknown
protein factors than unmethylated DNA sequences,
suggesting that differential methylation of the FABP3
promoter affects its binding with nuclear factors that
could regulate its gene expression in heart. Our ob-
served pattern suggests elevated levels of FABP3 pro-
moter methylation could recruit negative regulators of
transcription, as higher levels of CpG methylation of a
gene promoter has been associated with gene repression
[54,55].
Discussion
We conducted a statistical analysis of the hypothesized
association of epigenetic modifications of FABP3 gene
promoter with MetS traits, in a family-based population
of Northern European ancestry. We found that methyla-
tion states in blood cell-derived DNA are significantlyatus of FABP3
explained Change attributable to methylation P value
40 6.60 ± 0.045 0.00028
10 −0.18 ± 0.051 0.00253
70 −1.65 ± 0.050 0.00129
60 −0.39 ± 0.051 0.00144
each trait/CpG pair, β (±SE), total trait variance explained by the association
ecific CpG site are shown. *associations with confidence interval of 95%.
Figure 2 Manhattan plot of CpG methylation status in association with MetS traits. P-values for traits that were at least suggestively
significantly associated with methylation at one or more CpG sites [presented as –log(p) on the y-axis], were plotted against the chromosomal
positions of analyzed CpG sites. FABP3 is encoded on the - strand so bp locations (annotated to the + strand) are displayed in reverse order. Plot
symbol shapes represent specific MetS traits (see right margin of each panel). Symbols represent association of the 17 individual CpG loci as well
as the regional average (arbitrarily assigned to a position after the last CpG site). The gene architecture of the region is shown under the plots.
The dashed line represents the statistical significance threshold (blue, alpha=0.05) after correction for multiple testing.
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http://www.biomedcentral.com/1755-8794/6/9heritable in our families, and the methylation of several
individual CpG units as well as the regional average
methylation is significantly associated with MetS traits.
We also found that differential methylation at these
units affects the affinity of this region of DNA for bind-
ing to nuclear proteins extracted from human heart,
thus indicating a possible mechanism by which methyla-
tion may regulate gene-expression in this region. The
CpG island we identified near the transcription start site
of FABP3 is a 533 bp region spanning the promoter re-
gion and part of the first exon. There is evidence that
expression levels of various genes are influenced not just
by methylation of the promoter region, but also by
methylation status of the early exons and introns
[33,34]. In our study, we found that methylation levels
within the FABP3 promoter region were low (from 0.6%to 7.9%), but were dramatically higher (up to 95.6%) in
the first exon. Heritability appears to be strong for a ma-
jority of the individual CpG units in our families; both in
the promoter region and in the first exon, suggesting
that propensity for methylation at certain genomic loci
can be transmitted from generation to generation.
The proportion of variance in site specific methylation
that can be explained by age or sex was found to be
moderate with the highest effect size being approxi-
mately 2%, suggesting methylation may be influenced
more so by genetic (as our heritability estimates suggest)
and environmental factors. Still, while their effect sizes
were modest, age and sex did have a statistically signifi-
cant effect on methylation status at a number of CpG
units. FABP3_ 10/11/12, 14, 16 and 19 appeared to be
affected by both age and sex, whereas several units such
Table 4 Phenotypic characteristics of the expression cohort




Weight, kg 98.26 ± 24.01 88.43 ± 25.48
Height, cm 176.77 ± 7.35 165.17 ± 7.21
BMI, kg/m2 31.41 ± 7.37 32.44 ± 9.24
Waist circumference (WC), cm 96.25 ± 16.62 91.39 ± 20.47
Hip circumference (HC), cm 96.53 ± 17.13 100.91 ± 20.99
Waist to Hip ratio (WHR) 1.00 ± 0.11 0.91 ± 0.12
Fasting Glucose (FG), mg/dl 86.45 ± 23.69 88.41 ± 27.29
Fasting Insulin (FI),μU/ml 21.79 ± 22.60 19.02 ± 10.65
Homeostasis model assessment (HOMA) 4.72 ± 4.92 4.51 ± 4.04
Triglycerides (TG), mg/dl 117.53 ± 63.98 95.09 ± 41.08
Total cholesterol (TC), mg/dl 183.82 ± 36.36 182.10 ± 36.03
LDL-cholesterol (LDL-c), mg/dl 126.62 ± 33.69 121.93 ± 32.51
HDL-cholesterol (HDL-c), mg/dl 40.58 ± 10.50 47.64 ± 14.58
Adiponectin, ng/ml 10.04 ± 7.63 11.82 ± 5.59
Leptin, ng/ml 9.25 ± 9.04 24.87 ± 21.39
The mean +/− standard deviation is shown for each of the MetS phenotypes.
Figure 3 EMSA of differentially methylated FABP3 promoter
region. Completely methylated (M) or completely unmethylated
(UM), biotin-tagged DNA fragments were assayed for binding
activity using nuclear extract from human left ventricle tissue. The
location of the amplified region is depicted by the graph on the top
panel. The middle panel shows the EMSA results with biotin-labeled
free DNA at the bottom and protein-bound DNA at the top. The
lower panel shows UV fluorescence of the E-GelW fluorescent stain
(Invitrogen) (M or UM) after methylation-sensitive restriction enzyme
digestion by HPAII. Results are representative of at least three
independent experiments.
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http://www.biomedcentral.com/1755-8794/6/9as FABP3_2, 5, 6, 9 and 15, were only correlated with
age but not sex, and others, like FABP3_4, 8 and 20 were
influenced by sex but not by age. These results demon-
strate the complexity of epigenetic modifications and
their interaction with age and sex. Because the limitation
inherent in the EpiTYPER technology, some closely lo-
cated CpG sites were detected and reported as one
methylation “unit”. This needs to be considered when
interpreting the information of sites that were not distin-
guished as individual elements.
There is evidence that FABPs play the following roles
in tissue-targeted fatty acid management: assisting up-
take and trafficking of long-chain fatty acids (LFCAs);
targeting LCFAs for metabolic pathways (in muscle);
mediating lipid-mediated gene expression (adipose tissue
and macrophages); maintaining an intracellular pool of
LCFAs as cell fuel (mainly in muscle); and protecting
cellular proteins and membranes from the toxicity of
LCFAs and their derivatives [3]. Alterations in theTable 5 Correlations of FABP3 gene expression with MetS
traits related to lipids and adipokines
MetS trait β±SE P value
TC, mg/dl −0.25 ± 0.31 0.43
LDL-c, mg/dl −0.53 ± 0.31 0.09
HDL-c, mg/dl 0.42 ± 0.32 0.18
TG, mg/dl −0.20 ± 0.33 0.54
WHR −0.72 ± 0.37 0.05
Adiponectin, ng/ml 0.24 ± 0.39 0.53
Leptin, ng/ml −0.08 ± 0.46 0.86
For each trait, the β (±SE) and the p-value are shown.function of FABPs can therefore impact lipid metabolism
and cellular function in diverse tissues. Alterations in
FABP3 in particular, are associated with altered lipid me-
tabolism and cardiac and hepatic abnormalities in ani-
mal models. Mice lacking H-FABP showed a severe
defect in utilizing peripheral (non-fat and nonhepatic)
LCFAs [10]. In these mice the heart was forced to switch
to glucose fuel and the liver was burdened with in-
creased loads of LCFA oxidation. This H-FABP defi-
ciency made the heart intolerant to acute exercise and
eventually led to localized cardiac hypertrophy. In H-
FABP mutant mice models, exercise-induced elevation
in metabolic demands is dependent upon H-FABP to
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multiple tissues of the body [11]. Thus there are several
potential mechanisms by which alteration in FABP3
function could affect lipid metabolism and cardiovascu-
lar function in humans.
We found that the methylation level at several individ-
ual units as well as the average methylation level in the
region is associated with variation in multiple metabolic
syndrome phenotypes. Phenotypes that were associated
with FABP3 methylation included plasma lipids (TC,
LDL-c), lipoprotein sizing (BMED), blood pressure
(dBP), insulin sensitivity (SI). The size of these effects,
while generally less than 3%, is large enough to be of
clinical significance (for example, we found a mean vari-
ation of 6.60 mg/dl in total cholesterol for each 1%
change in average total methylation) and is comparable
to the effect sizes of single nucleotide polymorphisms
(SNPs) on complex disease traits [56,57]. In our study,
we have found that the variation in a Mets phenotype
that can be contributable to individual CpG site methy-
lation is comparable to the estimated effect sizes of an
individual SNP to a similar trait from previous studies.
This suggests that in this complex disease model, gen-
omic DNA methylation variation contribute in a similar
way as SNP variants do. That might be the reason that
we observe individual site contributes to only a small
portion of the total phenotype variance. Clinically how-
ever, this is meaningful because the changes in mean
levels of various risk factors are usually small, but even
small changes in mean levels can have a measurable
benefit at a population wide level [58]. Most intervention
trials using diet and drugs report mean alterations com-
parable to those seen in our population, but these are as-
sociated with significant decline in the incidence of
cardiovascular and other diseases [59,60]. In the case of
lipid phenotypes, the mechanism of these effects may be
directly related to the role of FABPs in lipid metabolism.
In addition, since FABPs may play a central role in co-
ordinating inflammatory and metabolic responses in the
cell, an alteration in gene function could influence the
levels of inflammatory cytokines and induce insulin re-
sistance. An effect on blood pressure has been reported
in an earlier study and may be mediated via insulin re-
sistance in skeletal muscle [21]. Taken together, these
observations suggest that alterations in methylation of
the FABP3 promoter region can be plausibly linked to
various biological precursors of metabolic syndrome.
Further studies will be conducted to ascertain how
methylation status is related to gene expression and
downstream physiologic effects in target tissues and ani-
mal models.
Since promoter CpG methylation is known to affect
the function of a gene by influencing the expression, we
conducted an analysis of correlations between thetranscript levels of FABP3 and several key MetS pheno-
types pertinent to lipid metabolism. Our data showed
that increased levels of FABP3 are correlated with mea-
sures indexing a beneficial metabolic profile whereas de-
creased levels of FABP3 are correlated with metabolic
profiles increase individual’s risk for developing cardio-
vascular diseases (CVDs) [61,62]. This suggests that in-
creased levels of FABP3 may benefit one’s metabolic
profiles. If taken together with the results of FABP3 pro-
moter methylation association with related traits, our
data show a consistent pattern in which lipid traits such
as plasma total cholesterol, correspond to higher methy-
lation levels of FABP3 at the promoter and lower expres-
sion levels of FABP3 in our surrogate tissue PWBCs. A
future study of bigger sample sizes may help strengthen
the statistical significance of the signals we obtained.
We further explored whether differential methylation
states of the core promoter region of FABP3, which a pre-
vious study had shown to be essential for the regulation of
the expression of this gene (53), could affect the binding
of transcription factors in a tissue of interest, the heart.
Our gel shift assay showed a clear difference between
completely methylated and completely unmethylated frag-
ments of the gene promoter region. This suggests a mo-
lecular mechanism for the associations that differential
methylation of FABP3 promoter alters binding capacity of
nuclear proteins that regulates FABP3 expression, which
in turn leads to variation in MetS phenotypes. The pattern
we observed here indicates that increased methylation
state of this region could contribute to the recruitment of
transcription repressors, if FABP3 transcription is under
the canonical regulation model where denser methylation
correspond to repressed transcription levels (54, 55). Our
assay was designed as a proof of concept to test the ex-
treme scenario of completely methylated region of interest
in comparison to its completely unmethylated counter-
part, however it may not reflect the endogenous physio-
logic conditions. This assay also does not demonstrate the
precise site that these factors bind to, nor did it identify
those factors. A study that addresses these questions could
provide valuable information and will be pursued in the
future.
Evidence recently published by the ENCODE project
demonstrated the extensiveness and universality of ele-
ments of the functional genome [63] and epigenetic tags
including CpG methylation and histone modification
codes are of pivotal importance in functional genomics
regulation [64-66]. We have found that in K562, a
leukemia cell line representing features of lymphocytes,
the promoter region of FABP3 that we investigated over-
laps with a region of peak signals for H3K4me1 and
H3K9ac, the two histone modification markers that are
usually indicative of active regulatory chromatin domain
for target gene expression [67-72]. This data together
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regulation in the cell. Further studies that address these
novel aspects in relation to phenotype expression may
be of importance to advance our understanding of
pathogenesis of MetS traits.
Conclusions
In summary, the current study provides evidence that
the methylation status of FABP3 is associated with phe-
notypes of metabolic syndrome. Our evidence character-
izing the heritability, age and sex effects on high
resolution CpG methylation provides initial insights into
the epigenetic regulation of an important biological gene
in humans. More research is needed to replicate our
findings and to elucidate the mechanisms and physio-
logic pathways through which methylation status affects
these phenotypes representative of cardiovascular func-
tion, lipid metabolism and insulin sensitivity. Our work
demonstrating the clinical relevance of the epigenetic
markers of an important biological candidate such as
FABP3 can be a step towards clinical tests that measure
epigenetic alterations that can predict patients’ risks of
developing insulin, lipids and blood pressure phenotypes
of MetS.
Additional file
Additional file 1: Table S1. PCR Primers for Methylation Detection of
the Promoter and First Exon region of FABP3. *Forward Primers contain
the T7 promoter tag (50 AGG AAG AGA G 30) on the 50 end of the primer
sequence. **Reverse primers contain the T7-promoter tag (50 CAG TAA
TAC GAC TCA CTA TAG GGA GAA GGC T 30) on the 50 end of the primer
sequence. Primers are complementary to the reverse (-) template strand.
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